Wuxi Hisky Medical Technologies Co Ltd, a Chinese medical device venture, has launched an innovative, non-invasive liver disease detection product. Called iLivTouch, the company uses multichannel imaging-guided transient elastography, a breakthrough in related medical technologies indicating advancements in local med-tech ventures.
Who is Wuxi Hisky Medical Technologies Co Ltd? (HISKY MED)
The company is a rapidly growing medical device-based venture specializing in non-invasive liver diagnosis. Founded in 2019, HISKY MED is headquartered in Wuxi, China and had two R&D centers in Wuxi and Beijing. Its self-developed non-invasive liver fibrosis diagnostic system, FibroTouch, is capable of making quantitative detection and assessment of liver fibrosis and hepatic steatosis with Transient Elastography (TE) technology. Fibrotouch was approved by the FDA in 2018.
Partnering with Asian Hospitals for NAFLD Patient Screening
It has been assumed that obesity and related diseases have been primarily an issue with the Western world. However, in Thailand liver specialists point out that the number of patients with obesity combined with metabolic syndrome has increased by 67% over the last few years.
Consequently HISKY MED has partnered with Thai hospitals including King Chulalongkorn Hospital and Vejthani Hospital, the leading reference hospitals in Thailand, to introduce HISKY MED’s FibroTouch® technology to screen and monitor NAFLD patients in these hospitals—representing a strategic step towards increase focus on NAFLD and increased use of their products in South East Asia.
iLivTouch; Chinese Moving from Followers to Leaders in Liver Disease Detection Space
Tissue elastography is an emerging diagnostic technique that uses ultrasound to differentiate between hard and soft tissues. This is purported to be the first breakthrough in medical ultrasound technologies for decades reports Qian Linxue, deputy president of China Association of Medical Equipment’s ultrasonic equipment and technology branch.
Qian continued “in high-end medical equipment in the world, Chinese companies are followers.” He continued “But after many years of research and development, Hisky Med has become a leader in related fields, improving the image of the Chinese domestic medical equipment sector.”
Peking University First Hospital touts the technology breakthrough as valuable as Xu Xiaoyuan, director of infectious disease reports that the new non-invasive technologies allow doctors to easily and accurately detect liver fibrosis and cirrhosis while traditional invasive methods are not always applicable, which is of great significance for the prevention and treatment of liver disease in China. Additionally, Jia Jidong, director of the liver disease research center under Beijing Friendship Hospital, Capital Medical University, reports that the new product can help overcome shortcomings of current clinical practice in liver disease treatment as it is non-invasive and helps with early detection.
Improving Chinese Liver Health—Earlier Detection
Apparently, in most cases, the biggest liver challenges for Chinese patients centers on viral hepatitis and non-alcoholic fatty liver. But because of symptoms often obscure and difficult to detect, the majority of Chinese patients are diagnosed at a later stage, often when surgery and drug treatments may be limited in effect.
Coming to America and Europe
CEO Shao Jinhua reports his company’s new product is based on patented technologies and the company that they and Tsinghua University developed together. This technology will improve liver scan accuracy in a user-friendly manner. CEO Jinhua notes they will expand to America and Europe after the China launch.
Call to Action: Interested in learning more about this liver detection technology, connect with CEO Shao Jinhua at HISKY MED.